Ensysce Biosciences (ENSC) said Monday it has regained compliance with Nasdaq's minimum stock price requirement for continued listing.
The pharmaceutical company said that since it had earlier regained compliance the exchange's stockholders' equity rule, it has now met all requirements outlined in a recent hearings panel decision, so its stock will continue trading on the Nasdaq Capital Market.
Price: 8.29, Change: +0.19, Percent Change: +2.35
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.